- Conditions
- Central Nervous System Neoplasms, Medulloblastoma
- Interventions
- Pomalidomide
- Drug
- Lead sponsor
- Celgene
- Industry
- Eligibility
- 1 Year to 21 Years
- Enrollment
- 53 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2023
- U.S. locations
- 6
- States / cities
- Stanford, California • Gainesville, Florida • Chicago, Illinois + 3 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1537–1560
of 17,842
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Dengue
- Interventions
- Pre-transfection F17, Post-transfection F17, Post-transfection F19, Placebo
- Biological · Other
- Lead sponsor
- U.S. Army Medical Research and Development Command
- Federal
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 86 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2006 – 2008
- U.S. locations
- 1
- States / cities
- Silver Spring, Maryland
- Conditions
- Cardiomyopathy, Renal Impairment
- Interventions
- Tadalafil, Placebo
- Drug
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 21 Years to 90 Years
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2019
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Covid19
- Interventions
- TQ Formula/Tab
- Drug
- Lead sponsor
- Novatek Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 55 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 3
- States / cities
- San Diego, California • Hialeah, Florida • Houston, Texas
- Conditions
- Human Immunodeficiency Virus
- Interventions
- 3BNC117-LS, Placebo
- Drug
- Lead sponsor
- Rockefeller University
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 43 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2020
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Painful Diabetic Neuropathy
- Interventions
- Oral dose CNTX-6016 or oral dose Placebo
- Drug
- Lead sponsor
- Centrexion Therapeutics
- Industry
- Eligibility
- 18 Years to 59 Years
- Enrollment
- 46 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2023
- U.S. locations
- 1
- States / cities
- Overland Park, Kansas
- Conditions
- Macular Degeneration, Age-Related Macular Degeneration, Choroidal Neovascularization, Wet Macular Degeneration
- Interventions
- Tiespectus, Aflibercept
- Drug
- Lead sponsor
- EyeBiotech Ltd.
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 960 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 60
- States / cities
- Gilbert, Arizona • Phoenix, Arizona • Encino, California + 56 more
- Conditions
- Diffuse Large B Cell Lymphoma, Primary Mediastinal Large B Cell Lymphoma, Transformed Follicular Lymphoma to Diffuse Large B Cell Lymphoma, Chronic Lymphocytic Leukemia, Indolent Non-Hodgkin Lymphoma, Marginal Zone Lymphoma, Waldenstrom Macroglobulinemia, Burkitt's Lymphoma, Primary CNS Lymphoma
- Interventions
- 19(T2)28z1xx CAR T cells
- Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2027
- U.S. locations
- 7
- States / cities
- Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
- Conditions
- Autistic Disorder
- Interventions
- Aripiprazole, Placebo, D-cycloserine
- Drug
- Lead sponsor
- Indiana University
- Other
- Eligibility
- 5 Years to 17 Years
- Enrollment
- 81 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2011
- U.S. locations
- 1
- States / cities
- Indianapolis, Indiana
- Conditions
- Hidradenitis Suppurativa
- Interventions
- Remibrutinib Dose A, Remibrutinib Dose B, Placebo 1, Placebo 2
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 12 Years to 100 Years
- Enrollment
- 565 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 35
- States / cities
- Birmingham, Alabama • Gilbert, Arizona • Fremont, California + 30 more
- Conditions
- Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia
- Interventions
- ADCT-301
- Drug
- Lead sponsor
- ADC Therapeutics S.A.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 11
- States / cities
- Atlanta, Georgia • Chicago, Illinois • New York, New York + 6 more
- Conditions
- Hemophilia B
- Interventions
- verbrinacogene setparvovec
- Genetic
- Lead sponsor
- Spur Therapeutics
- Industry
- Eligibility
- 18 Years to 65 Years · Male only
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 3
- States / cities
- Los Angeles, California • Tampa, Florida • Ann Arbor, Michigan
- Conditions
- Pancreatic Ductal Adenocarcinoma, Sarcoma
- Interventions
- Decitabine, Gemcitabine
- Drug
- Lead sponsor
- Mohammed Milhem
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2020
- U.S. locations
- 1
- States / cities
- Iowa City, Iowa
- Conditions
- Multiple Myeloma and Plasma Cell Neoplasm
- Interventions
- dexamethasone, sorafenib tosylate, Lenalidomide
- Drug
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2011
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Lymphoma, Leukemia, Myeloproliferative Disorders, Multiple Myleoma, Myelodysplastic Syndrome
- Interventions
- Rituximab, Fludarabine, Etoposide, Doxorubicin, Vincristine, Cyclophosphamide, Peripheral blood stem cell (PBSC) transplantation, T cell donor lymphocyte infusion (DLI) with unmanipulated donor T cells, Prednisone, Allogeneic hematopoietic stem cell transplant (HSCT), Filgrastim, T-Rapa cell Donor Lymphocyte Infusion (DLI)
- Drug · Procedure · Genetic
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 11 Years to 90 Years
- Enrollment
- 442 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2004 – 2017
- U.S. locations
- 2
- States / cities
- Bethesda, Maryland • Hackensack, New Jersey
- Conditions
- Acute Biphenotypic Leukemia, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, B-Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Hematologic and Lymphocytic Disorder, Hematopoietic Cell Transplantation Recipient, Myelodysplastic Syndrome, Primary Myelofibrosis, Secondary Myelofibrosis, T-Cell Non-Hodgkin Lymphoma, Thrombocytopenia, Venous Thromboembolism
- Interventions
- Platelet Transfusion
- Biological
- Lead sponsor
- Fred Hutchinson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Geographic Atrophy
- Interventions
- APL-2, Sham Procedure
- Drug · Other
- Lead sponsor
- Apellis Pharmaceuticals, Inc.
- Industry
- Eligibility
- 60 Years and older
- Enrollment
- 637 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 67
- States / cities
- Phoenix, Arizona • Bakersfield, California • Beverly Hills, California + 56 more
- Conditions
- Sickle Cell Disease
- Interventions
- TAK-755, Placebo
- Drug · Other
- Lead sponsor
- Shire
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 14
- States / cities
- Birmingham, Alabama • Little Rock, Arkansas • Aurora, Colorado + 11 more
- Conditions
- Breast Cancer, Metastatic Breast Carcinoma, Invasive Breast Carcinoma
- Interventions
- Carboplatin, Cyclophosphamide, Thiotepa, Stem Cell Transplant
- Drug · Procedure
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2012
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Acute Myeloid Leukemia
- Interventions
- Azacitidine, Venetoclax
- Drug
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 18 Years to 59 Years
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2026
- U.S. locations
- 1
- States / cities
- Aurora, Colorado
- Conditions
- Multiple Myeloma
- Interventions
- Bortezomib 1 mg/m2, Bortezomib 1.3 mg/m2, Bortezomib 1.6 mg/m2, Melphalan
- Drug
- Lead sponsor
- Hackensack Meridian Health
- Other
- Eligibility
- 18 Years to 76 Years
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2013
- U.S. locations
- 1
- States / cities
- Hackensack, New Jersey
- Conditions
- Narcolepsy, Idiopathic Hypersomnia
- Interventions
- Xywav, Placebo
- Drug · Other
- Lead sponsor
- Jazz Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 27
- States / cities
- Birmingham, Alabama • Cullman, Alabama • Daphne, Alabama + 23 more
- Conditions
- Head and Neck Cancer
- Interventions
- RAD001, Cetuximab, Cisplatin, Carboplatin
- Drug
- Lead sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2011
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Endometriosis
- Interventions
- OG-6219, Placebo
- Drug
- Lead sponsor
- Organon and Co
- Industry
- Eligibility
- 18 Years to 49 Years · Female only
- Enrollment
- 354 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 27
- States / cities
- Birmingham, Alabama • Los Angeles, California • Orange, Connecticut + 22 more